2 nd generation anti-androgens and radiotherapy for localized prostate cancer

Radiotherapy (RT) is one of the pillars of prostate cancer (PCa) treatments. Advanced in technology and clinical knowledge have allowed physicians to minimize treatments toxicity and improve clinical outcomes. Anti-testosterone treatments, commonly termed androgen deprivation therapy (ADT), are widely used in the treatment of both localized and metastatic PCa. ADT has proven to reduce tumor burden and improve clinically meaningful outcomes. Combining RT and ADT is the backbone of localized prostate cancer treatments in intermediate and high-risk disease; numerous prospective trials with long-term follow-up have demonstrated this combination to be superior to single modality therapy. In this review we will evaluate the role of Abiraterone and other 2nd generation anti-androgens in combination with RT